A phase 1/2 Trial assessing the safety and efficacy of bilateral intraputaminal and intranigral administration of cere-120 (adeno-associated virus serotype 2 (AAV2)-Neirturin (NTN) in subjects with Idiopathic Parkinson's disease

ID Number 09-1955

Principal Investigator(s)
Catherine Cho

Department(s) or Division(s)


This study is divided into two different phases. In phase 1 the purpose of the study is to test the effects of CERE-120 injections into both the Substantia Nigra and Putamen. In Phase 2, the purpose of the study is to test the possible benefits and safety of injecting CERE-120 into the brain of People with Parkinson's Disease.

Contact Information
Joan Bratton, Study Coordinator
(212) 241-0279

Recruiting Patients: Yes